Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Solomon, B. J.; Gettinger, S. N.; Riely, G. J.; Gadgeel, S. M.; Nokihara, H.; Han, J. Y.; Hida, T.; Satouchi, M.; Baldini, E.; Siena, S.; Yamamoto, N.; Horn, L.; Tassell, V. R.; Polli, A.; Camidge, D. R. |
| Abstract Title: | Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419602584 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.8105 |
| Notes: | Meeting Abstract: 8105 -- Source: Wos |
